Overview
Astria Therapeutics is a biopharmaceutical company focused on bringing life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE). At Astria, patients are our guiding stars. Our vision is a world where science, passion, and compassion create better todays and more tomorrows.